Skip to main
  1. Stocks
  2. Castle Biosciences Inc
  3. Forecast
CSTL

CSTL Stock Forecast & Price Target

CSTL Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Castle Biosciences is demonstrating durable fundamental momentum through an 11% Q3 revenue beat to $103M, 24% year-over-year revenue growth, and adjusted EBITDA of about $13M, showing that the business is scaling profitably while maintaining a 77% gross margin. The outlook is supported by multiple growth engines, led by TissueCypher’s 47% volume growth, DecisionDx-Melanoma’s fifth consecutive quarter above 10,000 tests, and early adoption of AdvanceAD-Tx, while management also raised 2026 revenue guidance to $385M-$395M. Reimbursement progress and pricing power add further upside, with potential SCC Medicare coverage in 2028, a strong crosswalk case for atopic dermatitis, and $278M of cash providing flexibility to invest prudently while still expecting positive adjusted EBITDA in Q4’26, FY2026, and FY2027.

Bears say

Castle Biosciences is facing a material reimbursement overhang because meaningful revenue from its SCC test is excluded after April 24, 2025, when Medicare payments stopped through Novitas, creating direct pressure on top-line visibility. The uncertainty around Medicare coverage for SCC is especially concerning because it is outside both the company’s guidance and the estimates, implying that near-term expectations may still prove too optimistic. More broadly, the company remains exposed to fluctuating government and commercial reimbursement rates, slow physician and payer adoption of new tests, competitive share loss, and the possibility that operating losses could require additional capital that may not be available.

CSTL has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Castle Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

CSTL Analyst Forecast & Price Prediction

Get the latest CSTL stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in CSTL

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Castle Biosciences Inc (CSTL) Forecast

Analysts have given CSTL a Strong Buy based on their latest research and market trends.

According to 7 analysts, CSTL has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Castle Biosciences Inc (CSTL)


CSTL Analyst Forecast & Price Prediction

Get the latest CSTL stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in CSTL

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CSTL stock data and trends